Epsilogen
London
About Epsilogen
IGEM Therapeutics is a developer of an immuno-oncology company intended to develop immunoglobulin antibodies to treat cancer.The company's offerings include IgE-based drugs targeting solid tumors, enabling patients to kill parasites which reside in human tissue, also the home of the solid tumor.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $69.4M
- Funding stage: Early Stage Venture
- Last round: Series B (Sep 2024)
- Website: epsilogen.com
- Phone: +44 (0) 203 657 7612
Industries & Categories
Biopharma, Biotechnology, Genetics, Life Science, Oncology
Social Profiles
Canonical: https://fsome.com/organization/epsilogen-25903 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.